Patients on benralizumab for asthma maintain control with reduced corticosteroid doses

Patients who take benralizumab for severe eosinophilic asthma can reduce their inhaled corticosteroid doses while maintaining asthma control for up to 48 weeks, according to a study published in The Lancet.
These findings support Global Initiative for Asthma (GINA) recommendations for reduced inhaled corticosteroid (ICS) doses for patients with severe asthma who have favorable responses to biologic therapy, the authors wrote.
“The results offer critical evidence for the potential for patients to safely reduce medication burden,” David J. Jackson, MBBS, MRCP, MSc, PhD, clinical

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart